Premium
Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre
Author(s) -
Minichsdorfer Christoph,
Jeryczynski Georg,
Krall Christoph,
Achhorner Alina Magdalena,
Caraan Ariane,
Pasalic Sabina,
Reininger Katharina,
Wagner Christina,
Bartsch Rupert,
Preusser Matthias,
Laggner Anton,
Raderer Markus,
Fuereder Thorsten
Publication year - 2021
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13623
Subject(s) - medicine , emergency department , covid-19 , cancer , emergency medicine , population , pandemic , medical emergency , disease , environmental health , psychiatry , infectious disease (medical specialty)
Background We investigated the influence of population‐wide COVID‐19 lockdown measures implemented on 16, March 2020 on routine and emergency care of cancer outpatients at a tertiary care cancer centre in Vienna, Austria. Methods We compared the number/visits of cancer outpatients receiving oncological therapies at the oncologic day clinic (DC) and admissions at the emergency department (ED) of our institution in time periods before (pre‐lockdown period: 1 January – 15 March 2020) and after (post‐lockdown period: 16 March– 31 May 2020) lockdown implementation with the respective reference periods of 2018 and 2019. Additionally, we analysed Emergency Severity Index (ESI) score of unplanned cancer patient presentations to the ED in the same post‐lockdown time periods. Patient outcome was described as 3‐month mortality rate (3‐MM). Results In total, 16 703 visits at the DC and 2664 patient visits for the respective time periods were recorded at the ED. No decrease in patient visits was observed at the DC after lockdown implementation ( P = .351), whereas a substantial decrease in patient visits at the ED was seen ( P < .001). This translates into a 26%‐31% reduction of cancer‐related patient visits per half month after the lockdown at the ED ( P < .001 vs. 2018 + 2019). There was no difference in the distribution of ESI scores at ED presentation ( P = .805), admission rates or 3‐MM in association with lockdown implementation ( P = .086). Conclusion We demonstrate the feasibility of maintaining antineoplastic therapy administration during the COVID‐19 pandemic. However, our data underline the need for adapted management strategies for emergency presentations of cancer patients.